Oncology
5,176 studies502 in 7 days2,477 in 30 days
Filters
Latest
5,176 studies
- 458 Impact of pretreatment steroid use on neutrophiltolymphocyte ratio in patients with NSCLC receiving immunotherapy-based frontline therapy
- 415 Mutations in FBXO38, a component of the SCF E3 ubiquitin ligase complex, dampen anti-tumor immunity
- 418 B cell regulation of anti-PD-1 immune checkpoint inhibition
- 1088 Identification and validation of novel shared neoantigen candidates utilizing whole exome sequencing of >340,000 patient samples
- 424 Tumour-homing T cells in the blood predict the efficacy of anti-PD-1 immunotherapy in melanoma patients
- 1047 Alternative splicing-derived tumor-specific antigens as putative immunotherapeutic targets for glioblastoma
- 977 An ICOS–IFN-γ T-cell signature links CNS immune-related adverse events and immune-mediated hepatitis following dual CTLA-4/PD-1 blockade
- 92 Construction and validation of alternative biomarker immunohistochemistry assays on the path to companion diagnostics
- 456 External validation of the SITC consensus definitions of primary and secondary resistance to immune checkpoint inhibitors in patients with solid tumors
- 882 BCG040, a novel B7-H4-targeting biparatopic ADC, demonstrates superior preclinical efficacy in heterogeneous tumors
- 837 Targeting a CD36-dependent macrophage immunometabolic program enhances PARP inhibitor response in BRCA-associated TNBC
- 697 Sex-biased macrophage polarization and CD8+ T cell suppression downstream of Yap1-CD276 signaling in medulloblastoma
- 605 Imneskibart, a human monoclonal antibody (mAb), + low-dose subcutaneous IL-2 + avelumab: phase 2 promising activity in CPI-refractory adenocarcinoma non-small cell lung cancer (NSCLC)
- 114 CXCL6 emerges as a novel marker of an immunosuppressive, angiogenic, and epithelial-mesenchymal transition (EMT)-enriched metastatic program in uveal melanoma (UM)
- 220 Overcoming antigen heterogeneity in Ewing sarcoma using adaptable multi-targeted SNAP-CAR T cells
- 514 Initial clinical results from START-002: a phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in triple-negative or HR+/HER2- mBC
- 822 CYT X300, a novel EGFR x pan-gamma delta T cell engager for the treatment of solid tumors
- Benchmarking Structural Variant Detection in Whole-Exome Sequencing of 67 Multiple Myeloma Cell Lines
- Feasibility of screening and brief intervention for multiple health behaviors within a mobile cancer prevention outreach program in underserved areas of Brittany, France
- Commonly expressed key driver genes in the pathogenesis of viral and non-viral liver cancer
- Male breast cancer in Northern Tanzania: Clinicopathology and predictors of two-year survival (2016–2022)
- 357 Mechanisms of LGALS3BP-driven resistance to TIL therapy
- 1010 HLA-B allele frequencies in immune checkpoint inhibitor-associated rheumatologic adverse events
- NRF2 and mutant p53 separately regulate redox balance in esophageal squamous cell carcinoma through metabolic reprogramming
- 191 In vivo metabolic imaging of GD2 CAR T cell dynamics against neuroblastoma